DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Alvocidib is an investigational drug.
There have been 63 clinical trials for Alvocidib. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 1997.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are National Cancer Institute (NCI), Tolero Pharmaceuticals, Inc., and Memorial Sloan Kettering Cancer Center.
Recent Clinical Trials for Alvocidib
|Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy||Tolero Pharmaceuticals, Inc.||Phase 2|
|Phase I, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors||Tolero Pharmaceuticals, Inc.||Phase 1|
|A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia||Tolero Pharmaceuticals, Inc.||Phase 1|